DIE SERUMLIPOIDKONZENTRATION VERMINDERNDE ARZNEIMITTEL

1,213,162. Pyridine derivatives. ASTRA A.B. 25 March, 1968 [23 March, 1967], No. 13687/67. Heading C2C. The invention comprises novel pyridine derivatives of the Formula I and therapeutically acceptable salts thereof, wherein Ri is H or Cl and A is a radical of the Formula II wherein n is 0 or 1 and B is a radical of the Formula IV above wherein m is 1 to 3 and R2 is H or Cl ; R1 being H when n is 1; not more than one of R1 and R2 being H when n is 0, m is 1 or 3 and B is a radical of general Formula IV, or a 2 - (p - chlorophenoxy) - isobutyl radical or wherein A is a radical of Formula III where R1 is H, D is a branched chain aliphatic hydrocarbon group containing not more than 12 carbon atoms or a 5 - methyl - pyrazol - 3 - yl or 2 - (p - chlorophenoxy) - 2 - propyl radical, and wherein, when R1 is Cl, D is a straight or branched, saturated or unsaturated aliphatic hydrocarbon group containing up to 12 carbon atoms, or a 5 - methylpyrazol - 3 - yl radical; and, when n is O, R1 is H and B is a 2 - (pchlorophenoxy) - isobutyl radical, the compound being optionally in the form of the N- oxide; and, when D is a 2 - (p - chlorophenoxy)- 2 - propyl, the compound being in the form of its N-oxide. Compounds of the above general Formula I wherein A is a radical of Formula II are prepared by reacting compounds of general Formula VIII wherein Z is COOH or a reactive derivative thereof with compounds of the formula wherein Y is halogen or OH and then if desired converting the compounds thus obtained into therapeutically acceptable salts, or when the compound is one wherein B is a 2 - (p - chlorophenoxy) - isobutyl radical, R1 is H and n is 0, oxidizing the compound to the corresponding N - oxide. Compounds of the above general Formula I wherein A is a radical of general Formula III are obtained by reacting a compounds of general Formula IV above wherein Y is halogen or OH with compounds of the general formula and if desired converting the compounds thus produced into therapeutically acceptable salts or, when the compound is one wherein D is a 2 - (p - chlorophenoxy) - 2 - propyl radical and R1 is H, oxidizing the compound to give the corresponding N-oxide. 5 - Fluoro - 3 - pyridinemethyl 5 fluoronicotinate is obtained either by reacting 5 - fluoronicotinic acid and 5 - fluoro - 3 - pyridinemethanol in anhydrous dioxane in the presence of N,N1 - dicyclohexylcarbodiimide or by reacting 5 - fluoro - 3 - pyridinemethanol with 5- fluoronicotinoyl chloride resulting from